Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
PharmaCyte Biotech, Inc. (NVLX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/04/2023 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
08/04/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
07/31/2023 10-K Annual Report for the period ended April 30, 2023
07/31/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/19/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
06/16/2023 SC 13D/A Iroquois Capital Management, LLC reports a 5% stake in PharmaCyte Biotech, Inc.
06/09/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/25/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
05/19/2023 SC 13G Ayrton Capital LLC reports a 10% stake in PHARMACYTE BIOTECH INC.
05/12/2023 SC 13D/A Iroquois Capital Management, LLC reports a 7% stake in PharmaCyte Biotech, Inc.
05/11/2023 SC TO-I Form SC TO-I - Tender offer statement by Issuer:
05/11/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...
Docs: "CERTIFICATE OF DESIGNATIONS OF PREFERENCES AND RIGHTS OF SERIES B CONVERTIBLE PREFERRED STOCK OF",
"Form of Warrant",
"Form of Purchase Agreement",
"Form of Registration Rights Agreement",
"Engagement Letter, by and between Synaptogenix, Inc. and Katalyst Securities LLC",
"For more information about the tender offer, contact the information agent:"
03/16/2023 10-Q Quarterly Report for the period ended January 31, 2023
02/08/2023 SC 13G/A INTRACOASTAL CAPITAL, LLC reports a 10% stake in PharmaCyte Biotech, Inc.
02/02/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:"
01/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
12/30/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
12/30/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/30/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/30/2022 8-K Quarterly results
12/14/2022 10-Q Quarterly Report for the period ended October 31, 2022
11/25/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/18/2022 8-K Quarterly results
11/16/2022 3 WEINSTEIN ROBERT (Director) has filed a Form 3 on PharmaCyte Biotech, Inc.
11/15/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
11/07/2022 8-K Quarterly results
10/20/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
10/14/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "RELEASE AGREEMENT"
10/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SEPARATION, CONSULTING AND RELEASE AGREEMENT",
"Investor Contact:"
09/14/2022 10-Q Quarterly Report for the period ended July 31, 2022
08/24/2022 3 Allen Daniel (Director) has filed a Form 3 on PharmaCyte Biotech, Inc.
08/23/2022 3 SCHECHTER JONATHAN (Director) has filed a Form 3 on PharmaCyte Biotech, Inc.
08/23/2022 3 STOVER JACK E (Director) has filed a Form 3 on PharmaCyte Biotech, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy